Company profile
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUEBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07119125 | phase1 | active_not_recruiting | 2025-06-27 | 2026-07-01 | Monte Rosa Therapeutics, Inc | A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP |
| NCT06597799 | phase1 | completed | 2024-08-07 | 2025-04-10 | Monte Rosa Therapeutics, Inc | First-in-human Study of MRT-6160 in Healthy Subjects |
| NCT07745361 | phase2 | recruiting | 2026-08-01 | 2027-10-01 | Monte Rosa Therapeutics, Inc | Study of Oral MRT-2359 With Apalutamide in Prostate Cancer |
| NCT05546268 | phase1_2 | active_not_recruiting | 2022-10-12 | 2026-05-01 | Monte Rosa Therapeutics, Inc | Study of Oral MRT-2359 in Selected Cancer Patients |
FDA applications (0)
No records yet.